Skip to main contentSkip to navigationSkip to search
SEK  %

Positive results from new study on influenza - CEO Claus Egstrand interviewed by BioStock

An in vitro study from the Medical University of Innsbruck shows that ColdZyme breaks the viral infection cycle and significantly reduces the viral load in human cells infected with influenza A. Enzymatica’s CEO Claus Egstrand visited BioStock’s studio to talk about ColdZyme and the study results.

Watch the interview on YouTube